Ligand, Viking Therapeutics preclinical data

In a mouse model of X-linked ALD, once-daily VK0214 significantly reduced plasma very long chain fatty acid levels by >25% from baseline to week 6 vs. vehicle-treated controls (p<0.01). Viking has exc...